BioNexus KC
30 W. Pershing Road
Suite 210
Kansas City MO 64108
Web and Phone Contact
Telephone (816) 753-7700
Fax 816- 285-0628
Mission Statement
We inspire thinkers from different disciplines to combine their efforts for a common purpose – healthcare innovation. From bioinformatics to cancer research and beyond, our goal is to provide the collaborative tools needed to showcase emerging technologies and bring them from conception to reality.
 
The KC region is a global leader at the nexus of human and animal health benefiting all our citizens and the economy. Our mission is to highlight life sciences resources and their value to the community through collaboration and commercialization. BioNexus KC creates opportunities at the nexus of:
  • Human and Animal Health
  • Academia and Industry
  • Kansas and Missouri
Leadership
CEO/Executive Director Mr. Dennis Ridenour
Board Chair William S. Berkley
Board Chair Company Affiliation Tension Corporation
History and Background
Year of Incorporation 1999
Former Names
Kansas City Area Life Sciences Foundation
Kansas City Area Life Sciences Institute
Volunteer Opportunities
Ways to donate, support, or volunteer

You can make a donation via our website, https://squareup.com/store/Bio-Nexus-KC.  Your donation to BioNexus KC, a not-for-profit organization, is tax deductible.

Financial Summary
Revenue Expense Area Graph

Comparing revenue to expenses shows how the organizations finances fluctuate over time.

Source: IRS Form 990

 Breakdown
Net Gain/Loss:    in 
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.
Statements
Mission Statement
We inspire thinkers from different disciplines to combine their efforts for a common purpose – healthcare innovation. From bioinformatics to cancer research and beyond, our goal is to provide the collaborative tools needed to showcase emerging technologies and bring them from conception to reality.
 
The KC region is a global leader at the nexus of human and animal health benefiting all our citizens and the economy. Our mission is to highlight life sciences resources and their value to the community through collaboration and commercialization. BioNexus KC creates opportunities at the nexus of:
  • Human and Animal Health
  • Academia and Industry
  • Kansas and Missouri
Background Statement
In 1999, the Kansas City Area Development Council (KCADC) & the Civic Council of Greater Kansas City collaborated to create a Life Sciences Task Force. This task force formed the Kansas City Area Life Sciences Institute (KCALSI) to develop a sustainable economic development advantage through successful implementation of the region’s life sciences plan. The plan identified several strategies from increasing research capacity, to commercializing products developed from research, to attracting new life sciences companies to the region.
 
In 2005, KCALSI coordinated the first regional life sciences strategic assessment, the "Kansas City Life Sciences & Convergent Technologies Road Map”. This data-driven process tracked every federal research dollar supporting life sciences research to identify research strengths. “Hot Teams,” comprised of academic, business, & civic leaders were formed to develop business plans for several scientific areas.
 
Out of this assessment, several impactful initiatives were launched, including the Animal Health Corridor, which was established in 2006 in cooperation with the KCADC and the Greater Kansas City Chamber of Commerce. The Corridor, which includes the region between Manhattan, Kansas and Columbia, Missouri, now represents more than 56% of global animal health, diagnostics and pet food sales.
 
In 2015, KCALSI completed its next strategic assessment, the "Path to 2025" and established its vision statement: The KC region is a global leader at the nexus of human and animal health benefiting all our citizens and the economy. BioNexus KC is a catalyst for innovation in animal and human health, whose role is to advance regional life sciences through research, commercialization and workforce development.
 
The regional focus of the organization involves:
  1. Research: (a) Grants to fund research to enable data generation for larger grants and additional federal investment in the region; (b) facilitate & and promote regional collaboration.
  2. Economic development & commercialization: (a) Facilitate and provide infrastructure for commercialization of regional innovations and the subsequent development of new companies; (b) partner in the attraction of new companies to the region.
  3. Science education & workforce development: (a) Promote/co-develop K-12 STEM education programs; (b) sponsor/present professional education events.
  4. Collaboration: Facilitate collaboration between our stakeholders and industry to develop new innovations and cures.
Impact Statement
2019 Accomplishments
1) New President & CEO: BioNexus KC President & CEO Dennis Ridenour was hired and started in Feb 2019.
 
2) 2018 Census: The 2018 Life Science Industry Census was released in early 2019.
 
3) Regional Life Sciences Strategic Assessment – “Path to 2025”:
   a)   Collaborate2Cure (C2C): The “Value-based Healthcare & Quality Outcomes” C2C series concluded in Nov 2019 after 18 months & over 1,000 attendees. The following two projects were selected for pilot programs:
      i) Opioid epidemic
      ii) Transitions in care, focusing on heart failure, leveraging insights into patients’ experiences & addressing the social determinants of health.
   b) Workforce Development:
      i) TIE Regional Advisory Council focusing on developing bioinformatics curricula to improve skilled workers.
      ii) Contract Research Organizations were identified as the second focus area.
   c) KC Nexus Fund: Preparing to launch the “KC Nexus Fund”, a Proof of Concept Fund (POC) that will invest in early stage animal & human health technologies. Animal & human health advisory committees will help evaluate opportunities & provide companies with guidance on the R&D activities needed to advance their technologies.
 
4) Research Development Grant Programs
   a) Blue KC “Transforming KC Health Research Grant” for $400K/2 years was awarded to a collaboration between The Community Health Council of Wyandotte County, KUMC, & Vibrant Health.
   b) Paul Patton Charitable Trust Grants: 3 grants to researchers at CMH & KUMC.
   c) Nexus of Human & Animal Health Grants: 3 grants to researchers at KUMC, KU & UMKC.
 
5) Educational Programs:
   a) One Health Research Symposium, Aug 2019: “Immunotherapy: Activating Your Immune System to Fight Disease”, ~110 attendees.
   b) “Midwest Bioinformatics Conference” Apr 2019: ~200 attendees.
   c) One Health Day, Nov 2019: “Climate Change & Extreme Weather Events”, 120 attendees.
 
2020 Goals
1) “Path to 2025” Execution
2) Launch the KC Nexus Fund
3) Expand Research Development Grant Program
4) Educational Programs
Needs Statement

Secure funding for specific programs:

  • Education & Research program funding ($300K/pear)
  • Research Development Grant funding ($550K/year)
  • Proof of Concept Fund ($6 million total)
  • Development of the regional innovation ecosystem ($100K/year)
  • General community support for implementing the regional life sciences vision, strategic objectives, and agenda ($250K/year)
Service Categories
Economic Development
Biological, Life Science Research
Medical Research NEC
Areas of Service
MO
KS
MO - Jackson County
MO - Clay County
MO - Platte County
KS - Wyandotte County
KS - Johnson County
MO - Eastern Jackson Co
MO - Jackson County Urban Core
KS - Wyandotte County Urban Core
CEO/Executive Director/Board Chair Statement

The Kansas City region is recognized as a life sciences leader because of our global strengths in animal health and agro-technology. Our excellence in top level researchers and our assets in human health, which represent two-thirds of our life sciences assets, continues to grow, especially in cancer research and care, and our unique strengths in Health IT and outcomes research.  Growing the life sciences in our region from Manhattan, Kansas to Columbia, Missouri has been BioNexus KC’s mission since our inception in 2000. BioNexus KC (formerly the Kansas City Area Life Sciences Institute) completed a Regional Strategic Assessment in 2015 to set a vision and plan for the next 10 years. This strategy included interviews with over 150 life science, business, and philanthropic leaders, and a widely distributed survey. Our region was benchmarked against 15 other leading life science clusters worldwide.

After an in-depth process, BioNexus KC’s vision statement was developed: The Kansas City region is a global leader at the nexus of human and animal health benefiting all our citizens and the economy. At the heart of this vision, is the understanding that we have a unique opportunity to distinguish the KC region because of our strengths in both animal and human health. The vision we have for KC being the nexus for animal and human health is achievable. It is more than an economic impact; it is an impact on the health of all the citizens in our community.

We have convened working groups to develop specific strategies in four scientific areas:

  1. Health Information Technology/Outcomes Research
  2. Animal Health
  3. Cancer Research and Care
  4. Neuroscience.

We also have convened task forces focusing on:

  1. Collaboration
  2. Workforce Development
  3. Capital Formation
  4. Messaging and Marketing.

These cross-cutting enablers are essential to create a well-developed infrastructure for sustaining our region’s success. The KC region will experience improved health outcomes and greater economic opportunities as we develop and capitalize on the animal and human health nexus and further each of the scientific areas and capabilities.

Programs
Description

We continue to execute on the regional life sciences strategy developed with Deloitte in 2015. Working groups for each of the four scientific areas identified as regional strengths – animal health, cancer care and research, neuroscience, and healthIT/outcomes research continue to develop and monitor projects. Similarly, task forces focused on key drivers of cluster enhancement – collaboration, capital formation, workforce development and messaging are actively monitoring projects. Each team manages specific strategies and objectives, monitors key metrics, and drives toward key project deliverables.

Program Budget $500,000.00
Category Medical Research, General/Other Medical Research, General/Other
Population Served General/Unspecified
Short-Term Success

The Collaboration Task Force developed an innovative model for increasing regional collaboration. Collaborate2Cure (C2C) targets an important research question and offers a financial incentive to fund new collaborative research. In 2018, the Health IT/Outcomes Research Working Group used the C2C platform to accelerate community solutions for critical healthcare problems. Two pilot projects were identified: 1) opioid crisis, and 2) transitions of care in chronic heart failure. The projects have collectively attracted 18 regional hospitals to participate.

The Neuroscience working group is focused on 2 regional opportunities, autism and cognitive decline with aging and Alzheimer’s. The autism group is developing an integrated health IT solution to track long-term outcomes in children with autism.

Long-Term Success

Our vision statement, “Kansas City is a global leader at the nexus of human and animal health benefiting all our citizens and economy,” defines our long-term objectives.  We have many programs driving these nexus opportunities.  We partnered with KSU and UMKC to develop 1Data, an interoperable database of animal health and human health data.  We are partnering with MU, KUMC, KSU and Children’s Mercy to create a clinical trial facility in KC to facilitate clinical trials in dogs and cats with naturally occurring disease to accelerate drug and device development for people and animals. We initiated research grants in 2017 to fund basic and applied research at the nexus of human and animal health.  We are developing a proof of concept fund at the nexus to ensure technologies have adequate funding to cross the “valley of death” and get on a path to commercialization. Throughout the year we actively promote “One Health,” the inextricable linkage of human, animal and plant health. 

Program Success Monitored By

Each working group/task force is responsible for developing the appropriate program metrics and deliverables that allow near real-time tracking of project progress. Collaborate2Cure measures program participation, regional engagement and publication metrics to assess long-term scientific collaboration. The Health/IT and Outcomes working group is measuring the number of hospitals that engage with proposed solutions to healthcare problems. The 1Data program is measuring total local, state and federal grant dollars to support the database in addition to external data sources added to the database. The cognitive decline working group is measuring the development of community resources committed to the problem and regional hospital engagement.

Examples of Program Success

We have many examples of success in addition to 1Data, value-based healthcare, autism and the cognitive decline programs listed above. We have integrated our workforce development efforts with KC Rising (Civic Council) to develop the regional advisory council that aligns industry and academia priorities to meet our current and future regional employment needs. We are developing a proof of concept funds that will provide access to capital for early stage technologies to ensure they have a path to commercialization. Our Collaborate2Cure program attracted hundreds of researchers and people across our community over the past three years to learn and contribute to opportunities in cancer immunotherapy, mitochondrial dysfunction, and value-based healthcare. $50,000 research grants funded new collaborative and innovative projects in each area.

Description The research grant program was one of our first and continues to be quite successful. In 2019 we funded one research grants in food insecurity through Blue-KC and three grants for childhood genetic diseases through the Patton family trust. Additionally, three research grants at the nexus of human and animal medicine were funded by the Hall Family Foundation. All researchers that submit a proposal receive a complete NIH-style written review regardless of their funding status so they can improve on future grant applications locally or nationally. Most importantly, the funding of their research proposals has resulted in an over 11:1 return on investment with over $11 in the form of additional grant dollars returning to the community for every $1 invested. The grants enable researchers to continue their research and quest for new treatments and better patient outcomes.
Program Budget $500,000.00
Category Science & Technology, General/Other Biological & Life Sciences
Population Served General/Unspecified, US
Program Frequently Assessed Yes
Short-Term Success

The immediate and short-term success of the research grants program is to drive collaboration and among our ten stakeholder institutions and encourage them to submit for significant federal funding opportunities through NIH and NSF. Some researchers are also able to quickly take the results from a $50,000 grant and receive significant federal funding. One example occurred this year when a nexus research grant yielded a federal grant for over $4.6 million.

Long-Term Success
Historically, the seed grants have enabled investigators to generate initial results that allow them to compete for larger federal research grants from agencies such as the National Institutes of Health and the National Science Foundation.
 
Since our inception, we have provided over $5 M in research grants to regional scientists to support new and innovative research to bring new cures and better outcomes to patients and animals. Importantly, these $5 million dollars have been leveraged and yielded over $58 M in follow-on federal funding for an ROI of 11.7:1.
Program Success Monitored By Funded grants are monitored with a six-month and final report. After the funding period, they are tracked for their ability to enable larger government grants, publications, presentations and scientific impact. The long-term return on investment is monitored by assessing the federal funding received following each research grant (generally valued at ~$50,000).
Examples of Program Success BioNexus-KC’s research grant program continues to be one of its most successful programs. In 2019, one research grants in food insecurity through Blue Cross and Blue Shield of Kansas City and three grants for childhood genetic diseases through the Paul Patton Trust, Ted C McCarter, William Evans Jr., and Bank of America, N.A. Trustees were funded. Funding of their research proposals has resulted in an over 11:1 return on investment in the form of additional grant dollars that come back to the community and to the researchers to continue their research and quest for new treatments and better patient outcomes.
Description
A workforce competent in math and science is essential for transforming the Kansas City region into a center of excellence in life sciences. We continue to work in K-12 STEM areas, including BioGENEius, an international competitive bioscience program for high school students. BioNexus-KC also co-sponsors the top award category for the Kansas City Science and Engineering Fair.
 
A key initiative underway in collaboration with KC Rising is focused on life sciences Talent-to -Industry Exchange (TIE). The process engages industry representatives and education providers to identify sector specific workforce needs to inform development of educational programs meeting those needs. The process was informed by a life sciences market assessment. Two key recommendations from the TIE process were to develop new curriculum in bioinformatics to support that industry cluster and to develop stackable credentials that are highly applicable to contract research organizations in the region.
Program Budget $75,000.00
Category Education, General/Other Partnerships in Education
Population Served Children and Youth (0 - 19 years), K-12 (5-19 years)
Program is linked to organization's mssion Yes
Program Frequently Assessed Yes
Short-Term Success
  • Support of BioGENEius and Kansas City Science and Engineering Fair raises awareness of STEM careers and increases Kansas City’s exposure nationally and internationally. We have had two national and international BioGENEius challenge winners in the past eight years.
  • Adult education programs showcase regional research expertise and enhance regional collaboration.
  • Increased opportunities for academic-industry partnerships.
Long-Term Success
  • Increased number of students choosing STEM careers.
  • Students prepared to enter the biotechnology workforce with skills needed by life sciences companies.
Program Success Monitored By
  • Number of students selecting biotechnology as a career choice.
  • Number of career readiness credentials granted.
  • Number of high school biotechnology students selecting collegiate STEM programs.
  • Numbers of collaborative grants funded.
  • Number of academic-industry partnerships.
Examples of Program Success
The BioGENEius has been an amazing success as stated above.
 
Our One Health Research Symposium every year is an opportunity for highlighting research and commercialization opportunities at the nexus of human and animal health. The One Health Symposium has led to a significant number of scientific collaborations at the nexus of animal and human health. We intentionally included students in all our professional development conferences to expose them to future employment, mentor and research opportunities.
 
Bioinformatic academic programs have been activated around our region. Most recently, two new bioinformatics programs were developed by the University of Central Missouri and the KU-Edwards campus.
Description Our strategic assessment identified the need for increasing available proof of concept funds that enable new life science innovations and technologies to progress more rapidly toward commercialization. We are launching a proof of concept funds in the nexus between animal and human health. The fund seeks to identify unique technologies that leverage opportunities in naturally occurring animal diseases to inform human drug development and vice versa.
Program Budget $150,000.00
Category Public, Society Benefit, General/Other Infrastructure
Population Served General/Unspecified
Program is linked to organization's mssion Yes
Program Frequently Assessed Yes
Short-Term Success

The proof of concept fund program received a $60,000 Technical Assistance grant from the US Economic Development Administration to develop the organizational structure of the funds.

Long-Term Success These combined activities will enhance the quality and efficiency of the region’s commercialization infrastructure, serving to move new innovations to market to benefit all citizens.
Program Success Monitored By
  • Numbers of projects in each fund portfolio
  • Specific milestones met per project
  • Number of public-private partnerships developed
  • Number of new products developed and patents issued
  • Follow on funding
Examples of Program Success

Successful proof of concept investments in technologies should demonstrate the value proposition of the project and begin measures to de-risk the technology to attract follow-on funding. 

Description Bioinformatics represents an important subcomponent of high-performance computing and has become a major focus area for the region and BioNexus-KC. The Kauffman Foundation provided funding to complete an assessment of bioinformatics capacity and capability between Manhattan, KS and Columbia, MO. The assessment determined the Kansas City region (as defined above) had assets equal to other parts of the country with established expertise in bioinformatics, although it was more geographically dispersed. To mitigate this issue, BioNexus-KC convenes the Midwest Bioinformatics Conference annually to promote regional collaboration.
Program Budget $75,000.00
Category Science & Technology, General/Other Computer & Information Science
Population Served Families
Program is linked to organization's mssion Yes
Program Frequently Assessed Yes
Short-Term Success

BioNexus-KC addressed a key recommendation for fostering regional bioinformatics collaboration by convening the Midwest Bioinformatics Conference. The two-day event is co-chaired by Keith Gary (BioNexus-KC) and Mark Hoffman (Children’s Mercy). In 2019, two nationally renowned speakers were included, along with 34 speakers from regional universities and companies. Approximately 200 attendees participated and 30 student posters were presented during the event. Three area company representatives conducted mock interviews for eleven students.

Long-Term Success

The conference is part of a two-prong approach to increase bioinformatics collaboration in the bi-state region.  A website was created listing the bioinformatics assets, capabilities, and expertise available at our ten stakeholder institutions. 

Program Success Monitored By
  • Numbers of collaborative federal funding proposals approved for funding
  • Numbers of collaborative bioinformatics journal articles accepted for publication
  • Website analytics indicating resource utilization
  • Number of public-private partnerships developed in bioinformatics
  • Number of degrees granted in bioinformatics
Examples of Program Success A number of collaborations have developed from the bioinformatics conference. One of particular interest is between a bioinformatics scientist at the University of Missouri and an autism investigator at Children’s Mercy. The former has technical expertise to assist the latter in handling the large amount of genomics data her studies generate. Planning for the next Midwest Bioinformatics Conference is underway and will be held in April 16-17, 2020.
CEO Comments
The KC region is a global leader at the nexus of human and animal health benefiting all our citizens and the economy. BioNexus KC is working within the current regional ecosystem to help develop and guide the regional life science and healthcare strategy. This includes highlighting life sciences resources and their value to the community through collaboration and commercialization efforts. Specifically, our initiatives fall within the following categories:
• Education & Research
• Research Development & Commercialization
• Proof of Concept and Early Stage Funding
• General community support for implementing the regional life sciences vision, strategic objectives, and agenda
In allocating its resources BioNexus KC routinely applies the following gating criteria questions.
• Does our involvement support our mission?
• Is the project or proposal aligned with our regional strengths?
• What are the chances of success and what benefits/returns could be achieved?
• Is there a viable business model and commercialization potential?
• At what level is the caliber of leadership and research capabilities?
• Do we have, or can we obtain, the resources to successfully undertake the effort and what is the potential to attract public/private funding?
• What is the opportunity to leverage other capabilities through collaboration?
We would welcome the opportunity to talk with interested individuals and institutions about progress in the regional life sciences, our programs and how they might support our efforts.
Executive Director/CEO
Executive Director Mr. Dennis Ridenour
Term Start Feb 2019
Experience

Dennis Ridenour became President and Chief Executive Officer of BioNexus KC in February of 2019. Prior to joining BioNexus KC, Mr. Ridenour was President and Chief Executive Officer of BioKansas, a regional life science & healthcare trade association based in Fairway, Kansas, where he managed all facets of the organization, including day-to-day operations, member development and engagement, strategic planning, and finance. Prior to joining BioKansas, Mr. Ridenour worked for 6 years at the Stowers Institute for Medical Research in Kansas City, MO, and at Merck Research Labs in Boston, MA, for 3 years. Mr. Ridenour started his professional career as a researcher in the Department of Neurobiology at Harvard Medical School. Dennis earned both a B.S. in Biological Sciences (1999) and an M.S. in Veterinary & Biomedical Sciences (2002) from the University of Nebraska-Lincoln, as well as an M.B.A. from the University of Kansas (2012).

Mr. Ridenour serves as Treasurer on the Board of Directors for RareKC, a non-profit whose mission is to accelerate the diagnosis, care and treatment of rare conditions, and as a member of the Board of Directors for the Alphapointe Foundation, a non-profit that works to empower people with vision loss to live, work and be independent. He also currently serves on several advisory boards, including those that support Kansas State University Olathe Campus, Wichita State University Biomedical Engineering, Olathe School District Bioengineering 21st Century Academy, and the Kansas State Science & Engineering Fair.

Co-CEO/Executive Director
Co-CEO/Executive Director BioNexus KC
Former CEOs
NameTerm
Dr. William P. Duncan PhDFeb 2001 - Apr 2009
Dr. Daniel P. Getman PhDApr 2009 - June 2012
Senior Staff
Title Vice President
Experience/Biography 2003-present: Director of Program Development, Kansas City Area Life Sciences Institute; 1998-2002: Joint Appointments in the Departments of Psychiatry and Pharmacology, University of Connecticut Health Center, Farmington, Connecticut; 1997-1998: Research Assistant Professor, Department of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire. Education: 1993 Ph.D. Biochemistry, University of Missouri, Kansas City, MO; 1982 B.A. Biology Central Methodist College, Fayette, MO; Postdoctoral Training: 1995-1997 Postdoctoral fellow, Department of Psychiatry, University of Pennsylvania School of Medicine; 1993-1995 Postdoctoral fellow, Neuropsychopharmacology Training Program, Department of Psychiatry, University of Pennsylvania School of Medicine; Occupational Experience: 1983-1988 Dialysis Technician, St. Luke's Hospital, Kansas City, Missouri. 1980-1983. Emergency Medical Technician-Paramedic, Howard County Ambulance Service, Fayette, Missouri. Awards and Honors: 1995-1997 Young Investigator Award, National Alliance for Research on Schizophrenia and Affective Disorders; 1998: Hitchcock Foundation Award, Dartmouth Medical School; 1999: RISE Award. Membership in Professional and Scientific Societies: American Association for the Advancement of Science; Histochemical Society; New York Academy of Sciences; Society for Neuroscience. Board of Directors: National Council on Alcoholism and Drug Dependence; Scientific Research Partners Credit Union.
Title Executive Assistant to the President and Office Manager
Experience/Biography As executive assistant for the KCALSI, Ms. Newman performs all administrative functions related to the President of the KCALSI and the daily operations of the Institute. Duties include financial record keeping; appointment scheduling; travel management; coordination and documentation of meetings for the board of directors as well as scientists representing research institutions, universities and hospitals in the Kansas City metropolitan area; and project management and coordination. In 2005 Ms. Newman received administrative professional certification from the International Association of Administrative Professionals. Previously, Ms. Newman has held positions as an executive secretary, office manager and medical transcriptionist. She attended college at Miami Dade Community College in Miami and Progressive College in Bulawayo, Rhodesia.   Ms. Newman is a Certified Administrative Professional with the International Association of Administrative Professions in 2005 and recertified in 2010.
Staff
Paid Full-Time Staff 4
Paid Part-Time Staff 2
Paid Contractors 2
Volunteers 32
Retention Rate 100%
Staff Diversity (Ethnicity)
Caucasian 6
Staff Diversity (Gender)
Female 3
Male 3
Formal Evaluations
CEO Formal Evaluation Yes
CEO/Executive Formal Evaluation Frequency Annually
Senior Management Formal Evaluation Yes
Senior Management Formal Evaluation Frequency Annually
Non-Management Formal Evaluation Yes
Non-Management Formal Evaluation Frequency Annually
Plans & Policies
Organization Has a Fundraising Plan Yes
Organization Has a Strategic Plan Yes
Management Succession Plan Yes
Organization Policy and Procedures Yes
Nondiscrimination Policy Yes
Whistleblower Policy Yes
Document Destruction Policy Yes
Collaborations
Existing collaborations with civic leadership organizations:
  1. Animal Health Corridor: Kansas City Area Development Council (KCADC)
  2. Regional Life Sciences: our ten stakeholders: Children’s Mercy Hospital, Kansas City University, Kansas State University, MRIGlobal, Saint Luke’s Health System, Truman Medical Centers, The University of Kansas, The University of Kansas Medical Center, The University of Missouri, The University of Missouri-Kansas City; and strategic partners: Civic Council of Greater Kansas City, Greater Kansas City Chamber of Commerce, Greater Kansas City Community Foundation, Kansas City Area Development Council, KC Animal Health Corridor, BioKansas. and MOBIO.
  3. KC Rising: Civic Council of Greater Kansas City, Greater Kansas City Chamber of Commerce, Kansas City Area Development Council
Awards
Award/RecognitionOrganizationYear
2006 Leadership AwardMid-America Regional Council2006
Government Licenses
Is your organization licensed by the government? No
CEO Comments

BioNexus KC is a catalyst for innovation in animal and human health. We inspire thinkers from different disciplines to combine their efforts for a common purpose – healthcare innovation. From bioinformatics to cancer research and beyond, our goal is to provide the collaborative tools needed to showcase emerging technologies and bring them from conception to reality.

BioNexus KC is an independent, third-party convening organization, leading the regional life sciences and executing on the strategy, “Path to 2025.” The strategy focuses on growing four scientific strengths, animal health, cancer research, value-based healthcare and neuroscience, and addressing four cross-cutting enablers that are necessary to build an effective life science ecosystem, including collaboration, workforce development, capital formation and marketing/messaging.

BioNexus KC has earned a reputation for fairness, honesty, and impartiality among public and private stakeholder organizations participating in the regional life sciences initiative.

Board Chair
Board Chair William Berkley
Company Affiliation Tension Corporation
Term Dec 2016 to Dec 2019
Email tcoomes@tension.com
Board Members
NameAffiliation
Mr. William S. BerkleyTension Envelope Corporation
Dr. D. Craig Brater MDIndiana University School of Medicine
Ms. Maria FlynnOrbis Biosciences
Mr. David FrantzeStinson Morrison Hecker LLP
Mr. Jeff HargrovesProPharma Group, Inc.
Mr. Irvine O. Hockaday Jr.Hallmark Cards, Inc
Madeleine McDonoughShook, Hardy & Bacon
Dr. Stephen L. Reintjes MDThe Kansas City Neurosurgery Group, LLC
Mr. Dennis RidenourBioNexus KC
Dr. Thomas M. Sack PhDMRIGlobal
Mrs. Anne D. St. PeterGlobal Prairie
Mrs. Deborah WilkersonGreater Kansas City Community Foundation
Board Demographics - Ethnicity
African American/Black 0
Asian American/Pacific Islander 0
Caucasian 12
Hispanic/Latino 0
Native American/American Indian 0
Board Demographics - Gender
Male 8
Female 4
Unspecified 0
Governance
Board Term Lengths 3
Board Term Limits 3
Board Meeting Attendance % 79%
Written Board Selection Criteria? Yes
Written Conflict of Interest Policy? Yes
Constituency Includes Client Representation Yes
Number of Full Board Meetings Annually 4
Standing Committees
Audit
Nominating
Advisory Board Members
NameAffiliation
Dr. Richard J. Barohn MDUniversity of Kansas Medical Center
Dr. Tom Curran PhD, FRSChildren's Mercy, Kansas City
Dr. Peter K. Dorhout PhDKansas State University
Dr. Mark Hecker PharmD, MBATruman Medical Centers
Dr. Mark McIntosh PhDUniversity of Missouri
Dr. Edward R. O'Connor PhDKansas City University
Dr. Timothy Pluard MDSaint Luke's Cancer Institute
Dr. John S. Stanley PhDMRIGlobal
CEO Comments

BioNexus KC believes we can do more to care for people and animals. We inspire thinkers from different disciplines to combine their efforts for a common purpose — healthcare innovation. From bioinformatics to cancer research and beyond, our goal is to provide the collaborative tools needed to showcase emerging technologies and bring them from conception to reality.


We seek opportunities to enhance and grow our regional capabilities and assets that translate into an enhanced quality of life and economic growth for the region. We increase the visibility of the Greater Kansas City region’s life science efforts and the opportunities at the local, state and national level.

Our volunteer board is composed of seasoned community leaders that provide guidance and expertise for BioNexus KC to achieve our regional vision and mission. The staff of BioNexus KC is committed to using all dollars judiciously to achieve our goals and grow the life science community.

Financials
Fiscal Year Start Jan 01, 2019
Fiscal Year End Dec 31, 2019
Projected Revenue $1,837,615
Projected Expenses $1,761,977
IRS Letter of Exemption
Foundation Comments
  • FY 2017, 2016, 2015: Financial data reported using the IRS Form 990.
  • Foundation/corporate revenue line item may include contributions from individuals.
Detailed Financials
 
Expense Allocation
Fiscal Year201820172016
Program Expense$1,531,444$1,435,206$1,032,369
Administration Expense$322,862$223,320$235,236
Fundraising Expense$15,080$56,372$102,912
Payments to Affiliates------
Total Revenue/Total Expenses0.970.361.33
Program Expense/Total Expenses82%84%75%
Fundraising Expense/Contributed Revenue------
Assets and Liabilities
Fiscal Year201820172016
Total Assets$1,940,310$2,003,174$2,014,840
Current Assets$1,894,536$1,990,906$1,999,582
Long-Term Liabilities$0$0$0
Current Liabilities$0$0$0
Total Net Assets$1,940,310$2,003,174$2,014,840
Short-Term Solvency
Fiscal Year201820172016
Current Ratio: Current Assets/Current Liabilities------
Long-Term Solvency
Fiscal Year201820172016
Long-Term Liabilities/Total Assets0%0%0%
Top Funding Sources
Fiscal Year201820172016
Top Funding Source & Dollar Amount -- --Anonymous $462,500
Second Highest Funding Source & Dollar Amount -- --Anonymous $250,000
Third Highest Funding Source & Dollar Amount -- --Anonymous $221,924
Capital Campaign
Currently in a Capital Campaign? No
Campaign Purpose Secure three-year operations funding. Secure ongoing programming support, especially for the seed grant program.
Capital Campaign Anticipated in Next 5 Years Yes
Organization Comments

BioNexus KC receives contributions each year that are designated for specific programs to be implemented in the current or following year.

BioNexus KC’s annual budget is ~$1.9 million. BioNexus KC stakeholder institutions contribute a third of our budget, with the remainder coming from philanthropic organizations, private sector companies and economic development entities. Strategic priorities are reviewed and approved annually by the BioNexus KC Board of Directors.

Approximately ~$500,000 are awarded through the BioNexus KC Research Development Program, aimed at generating preliminary data that support submission of major multidisciplinary research proposals. Since our inception, we have provided more than 100 grants totaling more than $5M in research grants to regional scientists to support new and innovative research to bring new cures and better outcomes to patients and animals. These grants have been highly leveraged and have had a tremendous impact on the region: for every $1 in BioNexus KC research grants awarded, more than $11.70 is returned in follow-on federal funding.

 

Other Documents
501c3 032020192019View
MO Sales Tax Exemption2014View
Organization Name BioNexus KC
Address 30 W. Pershing Road
Suite 210
Kansas City, MO 64108
Primary Phone (816) 753-7700
Contact Email snewman@bionexuskc.org
CEO/Executive Director Mr. Dennis Ridenour
Board Chair William S. Berkley
Board Chair Company Affiliation Tension Corporation
Year of Incorporation 1999
Former Names
Kansas City Area Life Sciences Foundation
Kansas City Area Life Sciences Institute